Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

NCT01069796 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

64

Enrollment

OTHER

Sponsor class

Stopped The number of inclusion was reached normally

Conditions

Triple Negative Metastatic Breast Cancer

Interventions

DRUG: Paclitaxel
DRUG: Bevacizumab
DRUG: Capecitabine

Sponsor

ARCAGY/ GINECO GROUP